Cancer is one of the most well-known diseases. The unfortunate fact is that the great majority of us have been or will be directly impacted by cancer, having been diagnosed, or having a close family member or acquaintance get ill. Over the years, there have been some great advances in cancer therapy, but there is still no cure. For most patients, the fate of a cancer diagnosis is largely determined by the effectiveness of the first diagnosis.
Pathology is critical in the diagnosis of many disorders, including cancer. It often entails the evaluation of tissue following a biopsy – and it is now entering a digital era.
Yvonne Sijm, investment manager at Health Innovations: “We believe that digital innovations enable the future of healthcare. Pathology plays an increasingly important role in many patient journeys. The solutions developed by Aiosyn support pathologists in providing high-quality decision-making. Aiosyn prepares the labor-intensive routine pathology tasks so that the pathologist can focus on the more interesting and complex tasks. This way, computational pathology not only makes life easier for pathologists, but it also helps in addressing the scarcity challenges.”
Dutch startup Aiosyn has developed AI-based tech that will work in close synergy with pathologists to address the growing workload and the demand to further improve diagnostic precision – ultimately improving outcomes for patients. Now, the startup has secured new funding and is set to accelerate development.
Aiosyn, a health-tech firm with a goal to use AI to enhance clinical diagnostics, has just raised €2 million. The Dutch firm intends to speed up the debut of its product.
Cancer is one of the most well-known diseases. The unfortunate fact is that the great majority of us have been or will be directly impacted by cancer, having been diagnosed, or having a close family member or acquaintance get ill. Over the years, there have been some great advances in cancer therapy, but there is still no cure. For most patients, the fate of a cancer diagnosis is largely determined by the effectiveness of the first diagnosis.
Pathology is critical in the diagnosis of many disorders, including cancer. It often entails the evaluation of tissue following a biopsy – and it is now entering a digital era.
Yvonne Sijm, investment manager at Health Innovations: “We believe that digital innovations enable the future of healthcare. Pathology plays an increasingly important role in many patient journeys. The solutions developed by Aiosyn support pathologists in providing high-quality decision-making. Aiosyn prepares the labor-intensive routine pathology tasks so that the pathologist can focus on the more interesting and complex tasks. This way, computational pathology not only makes life easier for pathologists, but it also helps in addressing the scarcity challenges.”
Dutch startup Aiosyn has developed AI-based tech that will work in close synergy with pathologists to address the growing workload and the demand to further improve diagnostic precision – ultimately improving outcomes for patients. Now, the startup has secured new funding and is set to accelerate development.
Source – E.U Startup.
